Germany
· Delayed Price · Currency is EUR ABIONYX Pharma Company Description
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.
It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis (NASH).
The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019.
ABIONYX Pharma SA was founded in 2005 and is headquartered in Balma, France.
| Country | France |
| Founded | 2005 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 51 |
| CEO | Cyrille Tupin |
Contact Details
Address: 33 43 Ave Georges Pompidou Bldg D2 Balma, 31130 France | |
| Phone | 33 5 62 24 97 06 |
| Website | abionyx.com |
Stock Details
| Ticker Symbol | 609 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Cyrille Tupin | Chief Executive Officer |
| Emmanuel Fougeroux | Chief Financial Officer |
| Constance Peyrottes | Chief Operating Officer |